SCHEMBL22979644

SCHEMBL22979644

CCOC(=O)c1cn(C2CC2)nc1CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.40
ELANE P08246 1/20 0.39
LMNA P02545 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
CSNK1D P48730 2/20 0.38
POLB P06746 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
HIF1A Q16665 1/20 0.37
DGAT1 O75907 1/20 0.37
GRK6 P43250 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
GLA P06280 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21816295 0.85 TSHR (0.42) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL26101331 0.84 TSHR (0.41) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL22897230 0.83 TSHR (0.40) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL1407095 0.83 CSNK1D (0.46) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL1407155 0.83 BAZ2B (0.43) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL22979883 0.82 NOTUM (0.38) LMNAMAPTDGAT1ALDH1A1MEN1
SCHEMBL21570236 0.82 TSHR (0.39) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL12984395 0.81 DGAT1 (0.52) TSHRELANELMNAGAADGAT1
SCHEMBL22979067 0.80 KDM4E (0.42) TSHRELANELMNAAKR1C3AKR1C2
SCHEMBL1407059 0.79 BAZ2B (0.39) TSHRELANELMNAAKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 TSHR 838/4885ELANE 3342/4885LMNA 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.